MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma

This contractor does not cover molecular biomarker tests intended to risk stratify individuals with cutaneous squamous cell carcinoma (cSCC). No molecular biomarker testing for cSCC risk stratification is payable under this policy.

"Molecular biomarker tests used to risk stratify individuals with cutaneous squamous cell carcinoma (cSCC) are not covered by this contractor."

Sign up to see full coverage criteria, indications, and limitations.